SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999; 341: 1051-1062.
  • 2
    Lowenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol. 1989; 7: 1268-1274.
  • 3
    Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: a Southwest Oncology Group study. Blood. 1997; 89: 3323-3329.
  • 4
    Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001; 98: 1302-1311.
  • 5
    Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol. 2007; 25: 1908-1915.
  • 6
    Malfuson JV, Etienne A, Turlure Pascal, et al. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica. 2008; 93: 1806-1813.
  • 7
    Frohling S, Schlenk RF, Kayser S, et al. Cytogenetics and age are the major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from the AMLSG trial AML HD98-B. Blood. 2006; 108: 63-73.
  • 8
    Kantarjian H, Ravandi F, O'Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukaemia. Blood. 2010; 116: 4422-4429.
  • 9
    Issa JP, Baylin SB, Herman JG. DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia. 1997; 11: S7-S11.
  • 10
    Desmond JC, Raynaud S, Tung E, Hofmann W-K, Haferlach T, Koeffler HP. Discovery of epigenetically silenced genes in acute myeloid leukemias. Leukemia. 2007; 21: 1026-1034.
  • 11
    Redner RL, Wang J, Liu JM. Chromatin remodeling and leukemia: new therapeutic paradigms. Blood. 1999; 94: 417-428.
  • 12
    Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol. 2005; 23: 3971-3993.
  • 13
    Garcia-Manero G. Demethylating agents in myeloid malignancies. Curr Opin Oncol. 2008; 20: 705-710.
  • 14
    O'Dwyer K, Maslak P. Azacitidine and the beginnings of therapeutic epigenetic modulation. Expert Opin Pharmacother. 2008; 9: 1981-1986.
  • 15
    Kuendgen A, Lubbert M. Current status of epigenetic treatment in myelodysplastic syndromes. Ann Hematol. 2008; 87: 601-611.
  • 16
    Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 1993; 7( suppl 1): 21-29.
  • 17
    Silverman LR, Holland JF, Demakos EP, et al. Azacitidine (Aza C) in myelodysplastic syndromes (MDS), CALGB studies 8421 and 8921 [abstract]. Ann Hematol. 1994; 68( suppl): A12. Abstract 46.
  • 18
    Kornblith AB, Herndon JE, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002; 20: 2441-2452.
  • 19
    Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002; 20: 2429-2440.
  • 20
    Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006; 24: 3895-3803.
  • 21
    Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with conventional care regimens in higher-risk myelodysplastic syndromes: results of a randomised, phase III study. Lancet Oncol. 2009; 10: 223-232.
  • 22
    Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100: 2292-2202.
  • 23
    Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010; 28: 562-569.
  • 24
    Blum W, Klisovic RB, Hackanson B, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol. 2007; 25: 3884-3891.
  • 25
    Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010; 28: 556-561.
  • 26
    Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003; 21: 4642-4649.
  • 27
    Grimwade D, Hills RK. Independent prognostic factors for AML outcome [serial online]. Am Soc Hematol Educ Program. 2009; 385-395.
  • 28
    Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108: 419-425.
  • 29
    Sudan N, Rossetti JM, Shadduck RK, et al. Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer. 2006; 107: 1839-1843.
  • 30
    Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007; 110: 2302-2308.
  • 31
    Silverman LR, Fenaux P, Mufti GJ, et al. The effects of continued azacitidine (AZA) treatment cycles on response in higher-risk patients (pts) with myelodysplastic syndromes (MDS) [abstract]. Blood (ASH Annual Meeting Abstracts). 2008; 112. Abstract 227.
  • 32
    Itzykson R, Thepot S, Recher C, et al. Azacytidine in refractory or relapsed AML after intensive chemotherapy (IC): results of the French ATU Program [abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114. Abstract 1054.
  • 33
    Thepot S, Itzykson R, Seegers V, et al. Azacytidine (AZA) as first line therapy in AML: results of the French ATU Program [abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114. Abstract 843.
  • 34
    Itzykson R, Thepot S, Quesnel B, et al. Prognostic factors of response and overall survival in 282 higher risk myelodysplastic syndromes treated with azacitidine. Blood. 2011; 117: 403-411.
  • 35
    Flasshove M, Strumberg D, Ayscue L, et al. Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside. Leukemia. 1994; 8: 780-785.
  • 36
    Richel DJ, Colly LP, Kluin-Nelemans JC, Willemze R. The antileukaemic activity of 5-AZA-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukemia. Br J Cancer. 1991; 64: 144-148.
  • 37
    Estey E, Thall P, Beran M, et al. Effect of diagnosis (refractory anemia with excess of blasts, refractory anemia with excess of blasts in transformation, or acute myeloid leukemia) on outcome of AML-type chemotherapy. Blood. 1997; 90: 2969-2977.
  • 38
    Bernstein SH, Brunetto VL, Davey FR, et al. Acute myeloid leukaemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B study. J Clin Oncol. 1996; 14: 2486-2494.
  • 39
    Tilly H, Castaigne S, Bordessoule D, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute non lymphocytic leukaemia in the elderly. J Clin Oncol. 1990; 8: 272-279.
  • 40
    Anderson JE, Kopecky KJ, Willman CL, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukaemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood. 2002; 100: 3869-3876.
  • 41
    Gardin C, Turlure P, Fagot T, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood. 2007; 109: 5129-5135.
  • 42
    Burnett A, Milligan D, Prentice AG, et al. A comparison of low dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007; 109: 1114-1124.
  • 43
    Burnett A, Russell NH, Kell J, et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol. 2010; 28: 2389-2395.
  • 44
    Kantarjian H, Erba H, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol. 2009; 28: 549-555.
  • 45
    Schiller G, O'Brien S, Pigneux A, et al. Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia. J Clin Oncol. 2009; 28: 815-821.
  • 46
    Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival (OS) and reduces infections and hospitalizations in patients (Pts) with WHO-defined acute myeloid leukemia (AML) compared with conventional care regimens (CCR) [abstract]. Blood (ASH Annual Meeting Abstracts). 2008: 112. Abstract 3636.